Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
August 30, 2004
- Approval of 4 NCEs Including Hepsera Recommended
August 30, 2004
- Kyorin to Continue License Accord with Merck & Co. on Joint Research in Antibacterials
August 30, 2004
- Wholesale Industry Should Standardize Ordering Systems: Kuraya Sanseido
August 30, 2004
- Korosho to Beef Up Drug Safety Measures: Dr Kurokawa
August 30, 2004
- Moroo Aims at 30% Market Share in Hokkaido
August 30, 2004
- REGULATORY NEWS IN BRIEF
August 30, 2004
- Towa to Use Pharmaceutical Technologies to Win Competition
August 30, 2004
- Sumitomo Pharm Focuses on 3 Fields of Drug Discovery
August 30, 2004
- Research Group Calls For Further Promotion of Generics
August 30, 2004
- Lipovas Lowers Stroke Risk by 25%: JAS Meeting
August 30, 2004
- Nichi-iko, Maruko to Form Business Tie-up
August 30, 2004
- TUT to Initiate Entrepreneur Program
August 30, 2004
- Toyobo to Embark on Contract Manufacturing in Earnest
August 30, 2004
- Iryo Proverbs Reveal Japanese Spirit (22)
August 30, 2004
- MBL, OTS Create Joint Venture to Develop Antibody Drugs
August 30, 2004
- Vitamins D3, K2 Are Second Choice Drugs for Steroid-induced Osteoporosis: GL
August 30, 2004
- JPMA to Survey Environment for Clinical Trials in Asia
August 30, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
August 30, 2004
- Semi-annual Business Results
August 23, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…